[HTML][HTML] Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Engineering self-assembling protein nanoparticles for therapeutic delivery
A Olshefsky, C Richardson, SH Pun… - Bioconjugate …, 2022 - ACS Publications
Despite remarkable advances over the past several decades, many therapeutic
nanomaterials fail to overcome major in vivo delivery barriers. Controlling immunogenicity …
nanomaterials fail to overcome major in vivo delivery barriers. Controlling immunogenicity …
[HTML][HTML] Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA. 1 and BA. 2
C Planchais, I Fernández, T Bruel… - Journal of Experimental …, 2022 - rupress.org
Disclosures: C. Planchais reported a patent to PCT/EP2022/058777 licensed (SpikImm). I.
Fernández reported a patent to PCT/EP2022/058777 licensed (SpikImm). T. Bruel reported …
Fernández reported a patent to PCT/EP2022/058777 licensed (SpikImm). T. Bruel reported …
[HTML][HTML] SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope
P He, B Liu, X Gao, Q Yan, R Pei, J Sun, Q Chen… - Nature …, 2022 - nature.com
Population antibody response is thought to be important in selection of virus variants. We
report that SARS-CoV-2 infection elicits a population immune response that is mediated by a …
report that SARS-CoV-2 infection elicits a population immune response that is mediated by a …
IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2
Humoral immunity to SARS-CoV-2 can be supplemented with polyclonal sera from
convalescent donors or an engineered monoclonal antibody (mAb) product. While …
convalescent donors or an engineered monoclonal antibody (mAb) product. While …
[HTML][HTML] Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Abstract The coronavirus disease 2019 (COVID-19) pandemic is an exceptional public
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …
[HTML][HTML] Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …
infected and nearly six million dead worldwide, making it the most significant pandemic …
A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2
Z Jia, K Wang, M Xie, J Wu, Y Hu, Y Zhou… - Protein & …, 2024 - academic.oup.com
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) has lasted for more than four years …
respiratory syndrome coronavirus-2 (SARS-CoV-2) has lasted for more than four years …
[HTML][HTML] Epitope profiling using computational structural modelling demonstrated on coronavirus-binding antibodies
SA Robinson, MIJ Raybould, C Schneider… - PLoS computational …, 2021 - journals.plos.org
Identifying the epitope of an antibody is a key step in understanding its function and its
potential as a therapeutic. Sequence-based clonal clustering can identify antibodies with …
potential as a therapeutic. Sequence-based clonal clustering can identify antibodies with …
[HTML][HTML] Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models
Nanobodies offer several potential advantages over mAbs for the control of SARS-CoV-2.
Their ability to access cryptic epitopes conserved across SARS-CoV-2 variants of concern …
Their ability to access cryptic epitopes conserved across SARS-CoV-2 variants of concern …